project id: TCGA-KIRC; case submitter id: TCGA-G6-A8L8; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.8; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.57; rna integrity number: 8.0; age at index: 62; days to birth: -22649; days to death: 1091; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Dead; year of birth: 1946; age at diagnosis: 22649; ajcc clinical m: MX; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage I; ajcc pathologic t: T1b; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 474.0; icd 10 code: C64.9; last known disease status: not reported; morphology: 8310/3; primary diagnosis: Clear cell adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Kidney, NOS; synchronous malignancy: No; tissue or organ of origin: Kidney, NOS; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1874; days to sample procurement: 0; initial weight: 150.0; portion submitter id: TCGA-G6-A8L8-01A-21; percent lymphocyte infiltration: 4.0; percent monocyte infiltration: 0.0; percent necrosis: 1.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 79.0; percent tumor nuclei: 95.0;